Neuroscientific Biopharmaceuticals Ltd. (AU:NSB)
ASX:NSB
NSB Stock Chart & Stats
AU$0.10
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.10
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.03 - AU$0.26
Previous CloseN/A
Volume70.60K
Average Volume (3M)306.60K
Market Cap
AU$33.26M
Enterprise ValueAU$32.15M
Total Cash (Recent Filing)AU$7.27M
Total Debt (Recent Filing)AU$0.00
Price to Earnings (P/E)―
Beta0.83
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding332,575,700
10 Day Avg. Volume291,172
30 Day Avg. Volume306,603
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)0.76
Price to Sales (P/S)0.00
P/FCF Ratio-13.54
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetA reported zero-debt position materially reduces solvency and interest-service risk over the medium term. That structural flexibility lets the company prioritize R&D and clinical timelines without mandatory fixed debt payments, improving survival odds through multi-year biotech cycles.
Positive Equity / Equity-funded AssetsSustained positive equity provides a capital cushion to absorb losses and supports further fundraising on less dilutive terms than distressed peers. Equity-funded assets imply lower leverage-related constraint on strategy, aiding long-term strategic investments in pipelines or partnerships.
Demonstrated Positive Operating Cash In 2024A modest positive operating cash flow year shows the business can occasionally convert activities into cash, indicating operational levers or transient revenue channels. That precedent increases the chance management can restore cash generation rather than permanently relying on external financing.
Bears Say
Revenue Collapsed To Zero (2025)Revenue falling to zero in 2025 is a structural red flag for long-term viability: it eliminates organic funding for operations, reduces ability to scale, and sharply increases reliance on external capital or partnerships to sustain R&D and commercial efforts over multiple quarters.
Persistent Cash Burn & Negative FCFConsistent negative operating and free cash flow erodes reserves and forces repeated financing, which can dilute shareholders and divert management focus to fundraising. Over 2-6 months this pressure magnifies funding risk and constrains long-term program execution.
Recurring Operating Losses And Negative ROESustained operating losses and mostly negative returns on equity indicate the company is not generating profitable operations. That undermines the ability to self-fund growth, weakens investor confidence, and signals structural issues in commercialization or cost structure that persist beyond short-term cycles.
Neuroscientific Biopharmaceuticals Ltd. News
NSB FAQ
What was Neuroscientific Biopharmaceuticals Ltd.’s price range in the past 12 months?
Neuroscientific Biopharmaceuticals Ltd. lowest share price was AU$0.03 and its highest was AU$0.26 in the past 12 months.
What is Neuroscientific Biopharmaceuticals Ltd.’s market cap?
Neuroscientific Biopharmaceuticals Ltd.’s market cap is AU$33.26M.
When is Neuroscientific Biopharmaceuticals Ltd.’s upcoming earnings report date?
Neuroscientific Biopharmaceuticals Ltd.’s upcoming earnings report date is Aug 27, 2026 which is in 145 days.
How were Neuroscientific Biopharmaceuticals Ltd.’s earnings last quarter?
Neuroscientific Biopharmaceuticals Ltd. released its earnings results on Feb 25, 2026. The company reported -AU$0.005 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.005.
Is Neuroscientific Biopharmaceuticals Ltd. overvalued?
According to Wall Street analysts Neuroscientific Biopharmaceuticals Ltd.’s price is currently Overvalued.
Does Neuroscientific Biopharmaceuticals Ltd. pay dividends?
Neuroscientific Biopharmaceuticals Ltd. does not currently pay dividends.
What is Neuroscientific Biopharmaceuticals Ltd.’s EPS estimate?
Neuroscientific Biopharmaceuticals Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Neuroscientific Biopharmaceuticals Ltd. have?
Neuroscientific Biopharmaceuticals Ltd. has 332,575,700 shares outstanding.
What happened to Neuroscientific Biopharmaceuticals Ltd.’s price movement after its last earnings report?
Neuroscientific Biopharmaceuticals Ltd. reported an EPS of -AU$0.005 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Neuroscientific Biopharmaceuticals Ltd.?
Currently, no hedge funds are holding shares in AU:NSB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Neuroscientific Biopharmaceuticals Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
265.85%
12-Months-Change
Fundamentals
Return on Equity
-19.10%
Trailing 12-Months
Asset Growth
232.64%
Trailing 12-Months
Company Description
Neuroscientific Biopharmaceuticals Ltd.
NeuroScientific Biopharmaceuticals Limited develops therapeutic treatments for neurodegenerative diseases through preclinical and clinical studies of patented technologies. Its lead drug candidates include EmtinB for treatment of neurodegenerative dementia and Alzheimer's disease, and degenerative conditions of the optic nerve. The company was incorporated in 2002 and is based in Cottesloe, Australia.
Technical Analysis
Cynata Therapeutics Limited
―
Prescient Therapeutics Limited
―
Starpharma Holdings Limited
―
Island Pharmaceuticals Ltd
―
AnteoTech Ltd
―
Options Prices
Currently, No data available
---